MicroRNA profiles in various hepatocellular carcinoma cell lines

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-associated mortality worldwide. Although surgery is considered the most effective treatment for patients with HCC, its indication is restricted by limited criteria and a high relapse rate following surgery; therefore, systemic chemotherapy is required for patients with advanced-stage HCC to prolong their survival. MicroRNAs (miRNAs) are endogenous non-coding RNAs of 18–22 nucleotides in length. It has been reported that aberrant expression of miRNAs is a feature shared by various types of human cancer. Previous studies have indicated that the modulation of non-coding RNAs, particularly miRNAs, may be a valuable therapeutic target for HCC. The aim of the present study was to elucidate the miRNA profiles associated with differentiation and hepatitis B virus (HBV) infection observed in HCC cell lines. The human Alex, Hep3B, HepG2, HuH1, HuH7, JHH1, JHH2, JHH5, JHH6, HLE, HLF and Li-7 HCC cell lines were used for an miRNA array. Replicate data were analyzed following their classification into: i) Poorly- and well-differentiated human HCC cells and ii) HBV-positive and -negative human HCC cells. Out of the 1,719 miRNAs, 4 were found to be significantly upregulated and 52 significantly downregulated in the poorly-differentiated cells, as compared with the well-differentiated cells. Conversely, in the HBV-positive cells 125 miRNAs were found to be upregulated and 2 downregulated, as compared with the HBV-negative cells. Unsupervised hierarchical clustering analysis with Pearson's correlation revealed that the miRNA expression levels were clustered both together and separately in each group. In conclusion, miRNA profile characterization based on various parameters may be a novel approach to determine the etiology of HCC.

[1]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[2]  H. Hsu,et al.  Clinical Management of Recurrent Hepatocellular Carcinoma , 1993, Annals of surgery.

[3]  Wenliang Li,et al.  Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation. , 2015, Pharmacology & therapeutics.

[4]  Hao Ren,et al.  Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. , 2012, World journal of gastroenterology.

[5]  T. Godfrey,et al.  MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. , 2011, The Annals of thoracic surgery.

[6]  T. Masaki MicroRNA and hepatocellular carcinoma , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[8]  Nathalie Wong,et al.  MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. , 2008, Gastroenterology.

[9]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[10]  Wang Renjie,et al.  MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. , 2015, Cancer letters.

[11]  Jian-Rong Yang,et al.  MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein , 2011, Nucleic acids research.

[12]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[14]  T. Takayama Surgical treatment for hepatocellular carcinoma. , 2011, Japanese journal of clinical oncology.

[15]  P. Małkowski,et al.  [Hepatocellular carcinoma--epidemiology and treatment]. , 2006, Przeglad epidemiologiczny.

[16]  C. Croce,et al.  Cyclin G 1 Is a Target of miR-122 a , a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma , 2007 .

[17]  Peter Schirmacher,et al.  MicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma , 2007, Hepatology.

[18]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[19]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[20]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[21]  Motohiro Kojima,et al.  MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers , 2015, PloS one.